Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.1K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.2K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

1.7K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.1K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.9K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients.

Critical care medicine·2023
Same author

Impact of adherence to procalcitonin antibiotic prescribing guideline recommendations for low procalcitonin levels on antibiotic use.

BMC infectious diseases·2023
Same author

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

JAMA·2022
Same author

Invited commentary on Sepsis.

Surgery·2022
Same author

Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era.

Open forum infectious diseases·2022
Same author

Proteomic changes associated with racial background and sepsis survival outcomes.

Molecular omics·2022
Same journal

When an Exacerbation Signals a Different Future in non-severe asthma.

American journal of respiratory and critical care medicine·2026
Same journal

Aim High-Stay Stable: Rethinking Treatment Success in COPD.

American journal of respiratory and critical care medicine·2026
Same journal

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

American journal of respiratory and critical care medicine·2026
Same journal

Signal in the Noise: Polygenic Scores and the Problem of Defining Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026
Same journal

Do mtDNA fragmentomic peaks reflect cancer biology or preanalytical and technical artifacts in NSCLC?

American journal of respiratory and critical care medicine·2026
Same journal

Short for Their Age: Interpreting Whole-Genome Telomere Length in Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 18, 2026

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

56.5K

Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis.

Roeland F Stolk1,2, Tom van der Poll3, Derek C Angus4

  • 11 Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

American Journal of Respiratory and Critical Care Medicine
|July 12, 2016
PubMed
Summary
This summary is machine-generated.

Norepinephrine, a common septic shock treatment, may worsen sepsis-induced immunoparalysis, increasing infection risk. Research is needed to explore alternatives like vasopressin and angiotensin II for better patient outcomes.

Keywords:
catecholaminescytokinesimmunoparalysisnorepinephrineseptic shock

More Related Videos

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

2.5K

Related Experiment Videos

Last Updated: Mar 18, 2026

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

56.5K
A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

2.5K

Area of Science:

  • Critical Care Medicine
  • Immunology
  • Pharmacology

Background:

  • Septic shock is a leading cause of mortality globally, posing a significant healthcare challenge.
  • The focus has shifted from pro-inflammatory responses to anti-inflammatory effects (sepsis-induced immunoparalysis) in sepsis pathophysiology.
  • Sepsis-induced immunoparalysis increases vulnerability to secondary infections and is linked to poorer patient outcomes.

Purpose of the Study:

  • To reevaluate current septic shock management strategies in light of the immunoparalysis hypothesis.
  • To investigate the potential detrimental role of norepinephrine, a primary treatment for septic shock, in exacerbating sepsis-induced immunoparalysis.
  • To explore the immunomodulatory effects of norepinephrine and alternative vasopressors.

Main Methods:

  • Review of current understanding of sepsis immunologic pathophysiology.
  • Detailed description of the immunomodulatory effects of norepinephrine and alternative vasopressors.
  • Analysis of in vitro and animal data regarding norepinephrine's effects on immune response and bacterial growth.

Main Results:

  • Norepinephrine may aggravate the development, extent, and duration of sepsis-induced immunoparalysis.
  • In vitro and animal studies suggest norepinephrine has immunosuppressive and bacterial growth-promoting effects, potentially increasing infection susceptibility.
  • Human evidence on norepinephrine's immunologic effects is circumstantial and lacks rigorous investigation.

Conclusions:

  • Novel therapies for reversing immunoparalysis are under development.
  • Norepinephrine's use may be detrimental in the context of sepsis-induced immunoparalysis.
  • Alternatives like vasopressin, selepressin, angiotensin II, and phenylephrine may offer immunologic advantages, but human in vivo data are scarce, necessitating further research.